Metformin + Linagliptin

Yes, Metformin + Linagliptin can cause some sleep problems, especially insomnia. On the other hand, Metformin + Linagliptin has proven to be useful for preventing sleep apnea. The exact relationship between Metformin + Linagliptin and sleep problems is still not clear, and further studies are needed for a clearer understanding.

Yes, you can take Metformin + Linagliptin with a beta-blocker. People with diabetes tend to develop heart disease or stroke at an earlier age than the general population. One reason for this is that high glucose levels increase your risk of high blood pressure (hypertension). No harmful interactions are seen between them. However, a recent study suggests that beta-blockers can decrease the plasma level of Metformin + Linagliptin and long-term use can increase lactic acid and uric acid in the blood.

Metformin + Linagliptin works by decreasing the hepatic glucose production. It also works to lower blood sugar by increasing your sensitivity to insulin and decreasing the amount of glucose that is absorbed from the food you eat.

Lactic acidosis associated with Metformin + Linagliptin treatment is a rare but fatal adverse effect. Lactic acidosis appears to result from biguanide interference causing an increase in production and decrease in clearance of lactate leading to higher cellular lactate levels. A decrease in pyruvate carboxylase activity, the rate-limiting enzyme in the formation of glucose from lactate, can also decrease hepatic metabolism of lactate. leading to increasing lactic acidosis. Signs and symptoms of Metformin + Linagliptin induced lactic acidosis are nonspecific and include anorexia, nausea, vomiting, altered level of consciousness, hyperpnoea, abdominal pain, and thirst. 

Yes, Metformin + Linagliptin can be taken with the statin. There is no serious or harmful interaction have been observed between them. Some studies say that it's possible your blood sugar (blood glucose) level may increase when you take a statin, which may lead to developing type 2 diabetes. The risk is small but important enough that the Food and Drug Administration (FDA) has issued a warning on statin labels regarding blood glucose levels and diabetes.